Drugs / SL-325
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | US (FDA) | — | inflammatory bowel disease | — | “today announced that the Company’s Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) for SL-325 for the treatment of...” shattucklabs.com ↗ “An IND was submitted to the FDA for SL-325 in July 2025; clearance expected in the third quarter of 2025.” shattucklabs.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07158437 | Sep 2025 → Jul 2026 overdue | — | Shattuck Labs, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-06-08 | Shattuck Labs, Inc. | Results Shattuck Labs Announces Phase 1 Results for SL-325 shattucklabs.com ↗
Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced data from its Phase 1 clinical trial of SL-325, Shattuck’s lead DR3 blocking antibody candidate. |
| 2025-08-21 | Shattuck Labs, Inc. | Regulatory Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease shattucklabs.com ↗
Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that the Company’s Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) for SL-325 for the treatment of inflammatory bowel disease is in effect. |
| 2025-02-20 | Shattuck Labs, Inc. | Results Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 shattucklabs.com ↗ |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SL-325 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07158437 ↗ |
| Action | Inhibit | “DR3 blocking antibody” NCT07158437 ↗ |